JNJ-Super company, Super stock! Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : JNJ-Super company, Super stock!

JNJ 188.87

-0.1%

Oct 31 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Rampex	1/26/2006 7:32:01 AM
	Read Replies (1) of 552

Perhaps after Tysabri is approved, J&J will buy Elan and dominate the multiple sclerosis therapy market. Serono, Teva, Berlex, and Biogen (which has half of Tysabri via Elan) are in deep trouble with their MS drugs. Soon those drugs will be essentially worthless. I am an MS sufferer and Elan investor so I am not unbiased. I also have two sisters with MS. We want Tysabri. Now. I need Elan to do well to help me pay the staggering cost of Tysabri. Perhaps a giant like J&J could bring down the cost for patients, insurers, and taxpayers with its economies of scale. All the best to J&J and Elan investors.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next